Related Experiment Video
Updated: Jul 8, 2026

Thermal Ablation for the Treatment of Abdominal Tumors
Published on: March 7, 2011
Short-Term and Long-Term Changes in Renal Function Following Percutaneous Cryoablation: A Comparison of Endophytic
Cathy Yu1, Matthew Hung1, Robin Wang1
1Division of Interventional Radiology, Department of Radiology, Stanford University School of Medicine, Stanford, California.
Purpose:
To determine the impact of endophytic vs exophytic tumor location on renal function following cryoablation.
Materials And Methods:
A retrospective review of 450 procedures in 392 patients who underwent percutaneous cryoablation of renal tumors over a 10-year period was performed. Two propensity score-matched cohorts of patients with endophytic and exophytic tumors were identified. Primary outcomes were change in estimated glomerular filtration rate (eGFR) at 3 months, 6 months, 1 year, and 3 years, and progression of chronic kidney disease (CKD) to or beyond Stage 3.
Results:
After propensity score matching, each cohort consisted of 89 patients who underwent technically successful procedures. At 3 months, eGFR declined by 7.1 mL/min/1.73 m2 from baseline in the endophytic group (P = .003), compared with 2.4 mL/min/1.73 m2 (P = .68) in the exophytic group. By 3 years, patients with endophytic and exophytic tumors demonstrated a comparable decline (7.7 and 5.9 mL/min/1.73 m2, respectively; P = .49). A greater proportion of patients with endophytic tumors progressed to CKD Stage 3b or higher at 1 year compared with those with exophytic tumors (10/76 vs 1/71; P = .01). At 3 years, there was no significant difference in proportion of patients who progressed to CKD Stage 3b or higher (7/65 vs 6/68, endophytic vs exophytic, respectively; P = .78).
Conclusions:
Percutaneous cryoablation of endophytic tumors is associated with early eGFR CKD stage progression, although the long-term impact on renal function is comparable with that of exophytic tumors.
Related Concept Videos
Kidney Transplant II: Surgical Procedure
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis
